AU2001284057A1 - Combination of lipoic acids and conjugated acids for treating diabetic disorders - Google Patents

Combination of lipoic acids and conjugated acids for treating diabetic disorders

Info

Publication number
AU2001284057A1
AU2001284057A1 AU2001284057A AU8405701A AU2001284057A1 AU 2001284057 A1 AU2001284057 A1 AU 2001284057A1 AU 2001284057 A AU2001284057 A AU 2001284057A AU 8405701 A AU8405701 A AU 8405701A AU 2001284057 A1 AU2001284057 A1 AU 2001284057A1
Authority
AU
Australia
Prior art keywords
acids
combination
diabetic disorders
lipoic
treating diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001284057A
Other languages
English (en)
Inventor
Kai-Uwe Baldenius
Oliver Hasselwander
Martin Jochen Klatt
Klaus Kramer
Loni Schweikert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of AU2001284057A1 publication Critical patent/AU2001284057A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001284057A 2000-09-12 2001-09-11 Combination of lipoic acids and conjugated acids for treating diabetic disorders Abandoned AU2001284057A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10045059.8 2000-09-12
DE10045059A DE10045059A1 (de) 2000-09-12 2000-09-12 Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen
PCT/EP2001/010501 WO2002022111A2 (de) 2000-09-12 2001-09-11 Kombination von liponsäure und konjuensäuren zur behandlung diabetischer störungen

Publications (1)

Publication Number Publication Date
AU2001284057A1 true AU2001284057A1 (en) 2002-03-26

Family

ID=7655916

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001284057A Abandoned AU2001284057A1 (en) 2000-09-12 2001-09-11 Combination of lipoic acids and conjugated acids for treating diabetic disorders

Country Status (10)

Country Link
US (1) US20030187058A1 (enExample)
EP (1) EP1317264B1 (enExample)
JP (1) JP2004508399A (enExample)
CN (1) CN1216602C (enExample)
AT (1) ATE271866T1 (enExample)
AU (1) AU2001284057A1 (enExample)
DE (2) DE10045059A1 (enExample)
DK (1) DK1317264T3 (enExample)
ES (1) ES2225593T3 (enExample)
WO (1) WO2002022111A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112113A1 (en) * 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US7914815B2 (en) * 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US8647612B2 (en) * 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US7935332B2 (en) 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US8697109B2 (en) * 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
EP1570752B1 (en) * 2004-03-06 2008-07-02 Cognis IP Management GmbH Verwendung von ungesättigten Fettsäuren zur Verringerung des Appetits oder der Essensaufnahme
GB0426264D0 (en) * 2004-11-30 2004-12-29 Trigen Ltd Compounds
JP4556061B2 (ja) * 2006-07-27 2010-10-06 ビーエイチエヌ株式会社 ヒアルロン酸産生増強剤
WO2008067403A2 (en) * 2006-11-28 2008-06-05 Encore Health Llc Presbyopia treatment by lens alteration
CN101396357B (zh) * 2007-09-29 2010-12-29 中国科学院上海生命科学研究院 硫辛酰胺在防治胰岛素抵抗中的用途
US9044439B2 (en) * 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
DK2442647T3 (en) 2009-06-15 2016-05-30 Encore Health Llc Dithiolforbindelser, derivatives thereof, and the uses of these
EP2442645B1 (en) 2009-06-15 2014-08-27 Encore Health, Llc Choline esters
CN101671331B (zh) * 2009-09-29 2011-06-01 寿光富康制药有限公司 硫辛酰维格列汀及其制备方法与应用
JP5245061B2 (ja) * 2010-05-12 2013-07-24 ビーエイチエヌ株式会社 経口用老化防止剤及び美容方法
CA2924597A1 (en) 2013-09-19 2015-03-26 The Research Foundation For The State University Of New York Methods and materials for treating diabetes or liver steatosis
WO2015050809A1 (en) * 2013-10-01 2015-04-09 Novozymes A/S Processes of producing fermentation products
CN106455563A (zh) 2014-03-03 2017-02-22 安可视觉公司 硫辛酸胆碱酯组合物及使用方法
WO2016160594A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4343593C2 (de) * 1993-12-21 1998-05-20 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
US5962030A (en) * 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
CA2313626A1 (en) * 1997-12-12 1999-06-17 Purdue Research Foundation Methods and compositions for treating diabetes
US6440931B1 (en) * 1999-02-23 2002-08-27 Natural Corporation Conjugated linoleic acid in treatment and prophylaxis of diabetes
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
US20020025310A1 (en) * 2000-02-02 2002-02-28 Bland Jeffrey S. Compositions and methods for promoting healthy joints

Also Published As

Publication number Publication date
CN1216602C (zh) 2005-08-31
JP2004508399A (ja) 2004-03-18
US20030187058A1 (en) 2003-10-02
ATE271866T1 (de) 2004-08-15
EP1317264A2 (de) 2003-06-11
ES2225593T3 (es) 2005-03-16
WO2002022111A3 (de) 2003-02-27
DE50103029D1 (de) 2004-09-02
DE10045059A1 (de) 2002-03-21
DK1317264T3 (da) 2004-11-29
WO2002022111A2 (de) 2002-03-21
CN1455670A (zh) 2003-11-12
EP1317264B1 (de) 2004-07-28

Similar Documents

Publication Publication Date Title
AU2001284057A1 (en) Combination of lipoic acids and conjugated acids for treating diabetic disorders
AU2004280090B2 (en) Dual alanyl aminopeptidase and dipeptidyl peptidase IV inhibitors for functionally influencing different cells and for treating immunological, inflammatory, neuronal and other diseases
BR9814484A (pt) "pró-drogas de inibidores de aspartil protease"
WO2001019776A3 (de) Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
WO2002062751A1 (fr) Nouveaux derives de cystine et inhibiteurs de l'activation des facteurs inflammatoires
IL148103A0 (en) Novel dicarboxylic acid derivatives with pharmaceutical properties
GEP20032987B (en) Stabilized Solid Compositions Containing Gamma-Aminobutyric Acid Derivatives for Treatment of Neuropathologic Diseases and Process for Preparing The Same
BR0306846A (pt) Produto substituto do sangue, composição útil como um substituto do sangue, método para fazer um produto substituto do sangue, e, método de uso de um produto substituto do sangue para fornecer oxigênio a um tecido
WO2002055496A8 (en) Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
EA200500377A1 (ru) Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DE60140491D1 (de) Verwendung einer pharmazeutischen Zusammensetzung mit einem Para-Aminophenylessigsäurederivat für die Behandlung von entzündlichen Erkrankungen des Magen-Darmtrakts
BG106155A (en) Novel derivatives and analogues of galanthamin
WO2003006443A3 (de) 2-`4-(naphtalin-2yl)-thiazol-2-ylaminocarbonyl benzoesäure und 2-`4-(naphtalin-2yl)-pyrimidin-2-ylaminocarbonyl benzoesäure und andere verbindungen als telomerase-hemmer zur anwendung in der tumortherapie
RU94038256A (ru) Производные пиразолопиримидина, способ их получения, фармацевтические композиции на их основе
DE60232173D1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
IL159241A0 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
CY1112057T1 (el) Θεραπευτικος παραγων για διαταραχη επαρκειας τροφης στο στομαχι
IL131216A (en) Drugs inhibiting progress of pterygium and postoperative recurrence of the same
CA2362833A1 (en) Phenylalaninol derivatives
EP1418910A4 (en) METHODS FOR INHIBITING OR REVERTING THE PROCESS OF FORMING TURF OR POLYMERIZATION FILAMENTS
WO2002009717A1 (en) Erectile dysfunction remedies containing prostaglandin derivatives as the active ingredient
TR199900584T2 (xx) Amino asit esteri i�eren azol mantar �nleyiciler.